✦ LIBER ✦

Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer

✍ Scribed by Jaime Coronel; Lucely Cetina; Myrna Candelaria; Aurora González-Fierro; Daimy Arias; David Cantu; Alfonso Dueñas-González

Book ID: 107576739
Publisher: Springer US
Year: 2008
Tongue: English
Weight: 194 KB
Volume: 26
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-008-9108-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly paclitaxel in patients with recur

Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer

✍ M. Tahara; H. Minami; Y. Hasegawa; K. Tomita; A. Watanabe; K. Nibu; M. Fujii; Y. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 240 KB

Utility of embolization or chemoemboliza

Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma

✍ Camillo Porta; Mauro Moroni; Giuseppe Nastasi; Enrico Bobbio-Pallavicini; Gianca 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 344 KB 👁 1 views

Utility of embolization or chemoemboliza

Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma

✍ Donald J. Martinelli; Scott Wadler; Curtis W. Bakal; Jacob Cynamon; Alla Rozenbl 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

Phase II studies on docetaxel alone ever

Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer

✍ M. Albertsson; B. Johansson; S. Friesland; L. Kadar; H. Letocha; G. Frykholm; G. 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 133 KB

Bevacizumab plus FOLFIRI or FOLFOX as th

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis

✍ Byung Woog Kang; Tae Won Kim; Jae-Lyun Lee; Min-Hee Ryu; Heung Moon Chang; Chang 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 188 KB

A randomised multicentre phase II trial

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

✍ Lee, J-L; Kang, Y-K; Kang, H J; Lee, K-H; Zang, D Y; Ryoo, B-Y; Kim, J G; Park, 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 161 KB